Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine - PubMed (original) (raw)

Jian-San Zhang, Nan Su, Jian-Guo Xu, Nan Wang, Jiang-Ting Chen, Xin Chen, Yu-Xuan Liu, Hong Gao, Yu-Ping Jia, Yan Liu, Rui-Hua Sun, Xu Wang, Dong-Zheng Yu, Rong Hai, Qiang Gao, Ye Ning, Hong-Xia Wang, Ma-Chao Li, Biao Kan, Guan-Mu Dong, Qi An, Ying-Qun Wang, Jun Han, Chuan Qin, Wei-Dong Yin, Xiao-Ping Dongs

Affiliations

Clinical Trial

Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine

Jiang-Tao Lin et al. Antivir Ther. 2007.

Abstract

Background: Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health.

Methods: To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control.

Results: On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later.

Conclusion: The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources